Quinoline derivative used for soft tissue sarcoma combination therapy

US12377089B2 · kind B2 · utility

Assignee

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

• Zhiming Wang · Sichuan, CN
• Shilong Zhang · Beijing, CN
• Rongyuan Zhuang · Shanghai, CN
• Xi Guo · Nanjing, CN
• Yan Wang · Jingwei, CN
• Hua Yang · Delta, CA
• Weiqi Lu · Shanghai, CN
• Yuhong Zhou · Conshohocken, US
• Lei Gao · Beijing, CN

Key dates

• Filing date: May 11, 2020
• Grant date: Aug 5, 2025
• Expiry date: Aug 31, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A quinoline derivative used for soft tissue sarcoma combination therapy, relating to a use of the quinoline derivative in combination with a second therapeutic drug to treat soft tissue sarcoma, wherein the second therapeutic drug may be a chemotherapy drug, a small molecule targeted anti-tumour drug or an immunotherapy drug. The chemical name of the quinoline derivative compound I is 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine.